Paper Details

  1. Home
  2. Paper Details

[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].

Author: BaoLi, HuangXiaojun, JiaJinsong, JiangBin, JiangHao, JiangQian, LuJin, WangJing, YangShenmiao, ZhangYuanyuan, ZhaoTing, ZhuHonghu

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

In adult patients with newly diagnosed acute myeloid leukemia (AML), a 10 mg/m² dose of idarubicin combined with cytarabine resulted in a significantly higher complete remission rate than an 8 mg/m² dose, with similar hematological side effects. The higher dose was also an independent favorable factor for disease-free survival and overall survival.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare the efficacy and toxicity of 10 mg/m² or 8 mg/m² idarubicin (Ida) combined with cytarabine (IA"3+7"regimen) as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia (AML). METHODS: From June 2004 to October 2013, 335 adult AML (non acute promyel...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342513/

データ提供：米国国立医学図書館（NLM）

Idarubicin and Cytarabine: Optimizing Induction Chemotherapy for Acute Myeloid Leukemia

Acute myeloid leukemia (AML), a rapidly progressing cancer of the blood, is like a wildfire raging across a desert landscape. This study compares the efficacy of two different doses of idarubicin, a chemotherapy drug, in combination with cytarabine for treating AML.

Higher Dose of Idarubicin: Improved Complete Remission Rates

The study compared the outcomes of 198 patients receiving 10 mg/m² of idarubicin and 137 patients receiving 8 mg/m² of idarubicin, both in combination with cytarabine. The results showed that the higher dose of idarubicin was associated with significantly higher complete remission rates, suggesting that it may be a more effective treatment option for AML. It's like finding a more powerful tool for extinguishing the wildfire, allowing for greater control and a better chance of complete eradication.

Navigating AML Treatment: Balancing Efficacy and Toxicity

This study highlights the importance of finding the optimal balance between efficacy and toxicity in AML treatment. It's like carefully navigating a desert landscape, seeking to achieve the best possible outcome while avoiding unnecessary risks. Further research is needed to refine the dosage of idarubicin and explore other potential combinations of chemotherapy drugs to maximize efficacy and minimize side effects.

Dr.Camel's Conclusion

This research provides valuable insights into the treatment of acute myeloid leukemia, emphasizing the importance of finding the optimal balance between efficacy and toxicity. It's like discovering a new well in the desert, offering a potential source of relief for those facing this challenging disease. By understanding the nuances of chemotherapy regimens and exploring new combinations of drugs, we can improve the chances of survival and enhance the quality of life for AML patients.

Date :
  1. Date Completed 2016-01-12
  2. Date Revised 2020-07-17
Further Info :

Pubmed ID

25854467

DOI: Digital Object Identifier

PMC7342513

Related Literature

Article Analysis
・Side Effects of idarubicin
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.